Veterinary Vaccines Market Report: Size, Share and Outlook by 2031

The veterinary vaccines market is anticipated to grow significantly, reaching an estimated US$ 15,536.38 million by 2028, up from US$ 9,984.65 million in 2021. This growth represents a compound annual growth rate (CAGR) of 6.5% from 2021 to 2028.

Veterinary vaccines are essential parenteral products designed to prevent infectious diseases caused by various pathogens. These vaccines play a vital role in protecting animals from numerous life-threatening illnesses. They are crucial for maintaining the health, longevity, and productivity of both pets and livestock in a cost-effective manner. Veterinary vaccines can be categorized into several types, including inactivated, live-attenuated, toxoid, and recombinant vaccines.

According to the World Health Organization (WHO), foodborne diseases (FBD) are a leading cause of illness and death worldwide, impacting approximately one-third of the global population annually. These diseases can arise from various sources, including chemical contaminants, bacteria, viruses, parasites, and biotoxins, and are often classified as neglected diseases. The transmission of FBD and its consequences pose significant threats to human health. With the growing human population and shifting dietary preferences towards higher protein consumption, the demand for animal products is projected to rise to 376 million tons by 2030. This increasing demand, along with heightened awareness of animal welfare, is driving changes in operational management within the industry.

Similar to humans, both pets and farm animals are vulnerable to a range of diseases caused by bacteria, viruses, fungi, and parasites. To combat these threats, various strategies, including veterinary vaccination, have been implemented. These vaccines are developed and approved under stringent regulatory frameworks to ensure their safety, efficacy, and quality. Vaccines targeting foodborne parasites not only enhance animal health by reducing infections but also contribute to public health by addressing a significant source of foodborne diseases. Furthermore, these vaccines help protect livestock by preventing or mitigating the risks associated with certain infectious diseases.

Healthy animals are fundamental to a nutritious food supply; thus, vaccinations are critical in ensuring the safety of animal-derived food products. The veterinary sector equips farmers with the necessary immunizations to safeguard the health and welfare of their animals.

In the realm of animal husbandry, the judicious use of antibiotics is emphasized, advocating for their application only when absolutely necessary to maintain animal health. This approach encourages the exploration of non-antibiotic alternatives for managing animal health and making informed decisions regarding antibiotic use when required. Vaccines present a viable alternative to the extensive use of antibiotics. A recent expert evaluation of alternatives to antimicrobial drugs in pig farming highlighted vaccinations as one of the top five methods in terms of perceived effectiveness and feasibility.

The global veterinary vaccines market is categorized based on vaccine type into livestock vaccines, companion animal vaccines, and other categories. The livestock vaccines segment is expected to dominate the market share in 2021. However, the companion animal vaccines segment is projected to experience the highest CAGR of 7.0% during the forecast period.

Additionally, the veterinary vaccines market is segmented by technology into live attenuated vaccines, inactivated vaccines, toxoid vaccines, recombinant vaccines, conjugate vaccines, and others. In 2021, live attenuated vaccines are expected to hold the largest market share, while the inactivated vaccines segment is anticipated to witness the highest growth rate from 2021 to 2028.

Key secondary sources utilized in the preparation of the report on the veterinary vaccines market include the National Institutes of Health (NIH), National Health Service (NHS), Centers for Disease Control and Prevention (CDC), National Chronic Kidney Disease, National Center for Biotechnology Information, National Statistics Institute, and the World Health Organization (WHO).